At 47.6% CAGR, the Asia Pacific Enzymatic DNA Synthesis Market is projected to be worth US$ 301.49 million by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific enzymatic DNA synthesis market  was valued at US$ 29.18 million in 2022 and is expected to reach US$ 301.49 million by 2028, registering a CAGR of 47.6% from 2022 to 2028. Rising prevalence of genetic disorders and surging number of product launches are the critical factors attributed to the Asia Pacific enzymatic DNA synthesis market expansion.        

Personalized medicine means improving healthcare by incorporating early disease detection, preventive medicine, rational drug discovery and development, and therapy monitoring. The genetic profile of a patient assists doctors in precisely calculating a patient's susceptibility to specific diseases and allows them to prescribe the patient a proper medication with reduced side effects. The bottom-up synthetic biology approach is considered more relevant for developing personalized medicine as it offers more flexibility in building a semi-synthetic cell from molecular building blocks for a desired application. Enzymatic DNA synthesis is expected to make a significant contribution to personalized medicine. It can be used to explore any possible mutations or gene variants affecting a patient's response to a particular drug/treatment by analyzing the patient's genome sequencing or microarray gene expression. Moreover, enzymatic DNA synthesis may furnish better conclusions in the prior identification of infection. Therefore, personalized medicine, especially for treating rare diseases and genetic disorders, is expected to bring new trends in the Asia Pacific enzymatic DNA synthesis market. New storage technologies are required to keep up with the global needs of data generation. Genetic code is millions of times more efficient at storing data than existing solutions, which are expensive and consume immense amounts of power and space. DNA as a high-density data storage medium can drive breakthroughs in next-generation biosensing and bio-recording technology, and digital storage. DNA data storage is experiencing incredible growth with even non-bio giants, such as Microsoft, entering the space. Enzymatic synthesis of DNA is considered to be a promising option. Enzymatic systems synthesize DNA that records rapidly changing environmental signals directly into DNA sequences, a method that could change how scientists study and record neurons in the brain. Thus, growing efforts to harness multiplex enzymatic oligonucleotide synthesis in the context of important applications such as digital data storage will usher in a new era of scientific research and biotechnology.

On the contrary, high cost and complex procedures hampers the Asia Pacific Enzymatic DNA Synthesis Market 

Based on product type, the Asia Pacific enzymatic DNA synthesis market is segmented into custom DNA synthesis and DNA library synthesis. The DNA library synthesis held 54.6% share of Asia Pacific Enzymatic DNA Synthesis Market in 2022, amassing US$ 15.94 million. It is projected to garner US$ 160.15 million by 2028 to expand at 46.9% CAGR during 2022–2028. 

Based on application, the Asia Pacific enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held 50.9% share of Asia Pacific Enzymatic DNA Synthesis Market  in 2022, amassing US$ 14.86 million. It is projected to garner US$ 151.29 million by 2028 to expand at 47.2% CAGR during 2022–2028.

Based on technology, the Asia Pacific enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment held 46.1% share of Asia Pacific Enzymatic DNA Synthesis Market  in 2022, amassing US$ 13.46 million. It is projected to garner US$ 136.35 million by 2028 to expand at 47.1% CAGR during 2022–2028.

Based on end user, the Asia Pacific enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech and pharmaceutical companies segment held 53.0% share of Asia Pacific Enzymatic DNA Synthesis Market  in 2022, amassing US$ 15.48 million. It is projected to garner US$ 156.44 million by 2028 to expand at 47.0% CAGR during 2022–2028.

Based on country, the Asia Pacific enzymatic DNA synthesis market  has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% share of Asia Pacific Enzymatic DNA Synthesis Market  in 2022. It was assessed at US$ 8.54 million in 2022 and is likely to hit US$ 87.28 million by 2028, exhibiting a CAGR of 47.3% during the forecast period.

Key players dominating the Asia Pacific enzymatic DNA synthesis market are DNA Script; GenScript Biotech Corporation; Synbio Technologies; Touchlight; and Twist Bioscience, among others.   

• In Feb 2023, Evonetix has completed a US$24 million financing round, extending its entire series B funding to over US$54 million. Existing investor Foresite Capital led the fundraising and others. The investment will enable the continued development of Evonetix’s semiconductor chips on a commercial scale.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com